Insights on the Diabetic Foot Ulcer Global Market to 2028 - Featuring Coloplast, Medline Industries and Cardinal Health Among Others prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
North America Feeding Tubes Market to Reach USD 1,014.9 Million by 2028; Rapid Shift towards Enteral Feeding to Boost Growth, says Fortune Business Insights™ Key Players Covered in the North America Feeding Tubes Market are Cardinal Health (Ohio, United States), BD (Becton, Dickinson and Company) (New Jersey, United States), B. Braun Melsungen AG (Melsungen, Germany), Avanos Medical Inc (Georgia, United States), Baxter (Deerfield, United States), Vygon SA (Écouen, France), Applied Medical Technology, Inc. (Ohio, United States), Other Prominent Players
April 20, 2021 10:06 ET | Source: Fortune Business Insights Fortune Business Insights
Pune, India, April 20, 2021 (GLOBE NEWSWIRE) The
North America feeding tubes market is set to gain momentum from the increasing shift of people towards enteral feeding from parenteral feeding because of its several benefits. It promotes the local immune function of the gut and eliminates villous
leading cause of non-traumatic lower extremity amputations in the United States, and approximately
14-24% of patients with diabetes who develop a foot ulcer will require an
amputation. Foot ulceration precedes
85% of diabetes-related amputations.
The gold standard for Diabetic Foot Ulcer treatment includes debridement of the wound, management of any infection, revascularization procedures when indicated, and off-loading of the ulcer.
Currently, the market is mainly dominated by
off-label generic drugs such as analgesics and anti-infectives,
around 78% of the current market is captured by these two classes of drugs.
There is only one drug,
Regranex (Becaplermin), which the FDA has approved.
Regranex gel uses a Platelet-derived growth factor (PDGF) for the Diabetic Neuropathic Ulcer treatment formulated to act as a first-line treatment following effective ulcer care. The US FDA had approved the biologics license application of Becaplermin (OMJ Pharmaceuticals, Inc